cancer vaccine 2000
2000-08-31
org.kosen.entty.User@4359d3a2
김수기(sk302)
행사&학회소개
보고서작성신청
CANCER VACCINES 2000
An International Symposium Sponsored by the Cancer Research Institute
October 2-4, 2000
Manhattan Conference Center
At the Millennium Broadway, 145 West 44th Street, New York City
The eighth meeting in CRI's Symposia Series will cover a broad range of topics, including:
Tumor antigen identification
Monitoring immune response to tumor antigens
Mechanisms of tumor antigen presentation
Effector cell generation and memory
Tumor escape routes
Vaccine constructs
Cytokine and non-cytokine adjuvants
Current status of clinical trials
A preliminary list of speakers includes:
Lloyd J. Old, M.D., Conference Chairman, Ludwig Institute for Cancer Research, New York, NY
Vincenzo Cerundolo, M.D., Ph.D., John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
Glenn Dranoff, M.D., Dana-Farber Cancer Institute, Boston, MA
Philip D. Greenberg, M.D., University of Washington, Seattle, WA
Alexander Knuth, M.D., Krankenhaus Nordwest, Frankfurt, Germany
Martin C. Mihm, M.D., F.A.C.P., Massachusetts General Hospital, Boston, MA
Haruo Ohtani, M.D., Tohuku University Graduate School of Medical Science, Sendai, Japan
Pedro Romero, Ph.D., Ludwig Institute for Cancer Research, Lausanne, Switzerland
Steven A. Rosenberg, M.D., Ph.D., National Cancer Institute/NIH, Bethesda, MD
Robert D. Schreiber, Ph.D., Washington University School of Medicine, St. Louis, MO
Gerold Schuler, M.D., Dermotologische Universitaet Klinik, Erlanger, Germany
Pramod K. Srivastava, Ph.D., University of Connecticut, Farmington, CT
Tiny comments on CV2000 :
1) This conference is regarded as a best meeting in a field of tumor immunology.
2) The Cancer Research Institute(sponser org.) was founded in 1953 to foster the science of cancer immunology, which is based on the premise that the body's immune system can be mobilized against cancer. This field, which CRI helped pioneer and develop, has been recognized throughout the world as offering great hope for the ultimate prevention and treatment of human cancer.
For nearly five decades, the Institute has been a sustaining force in cancer and immunology research. The Institute has supported nearly 1000 scientists and clinicians at leading universities and research centers worldwide. All such funding decisions are made by its Scientific Advisory Council consisting of 64 of the world's leading immunologists, including five Nobel Prize winners and 18 members of the National Academy of Sciences.
3) I have attended this meeting 2 years(98-99) consecutively.
However, I never seen a Korean immunologist even though this field has been still rapidly progressing.
This year, I am gonna attend and grasp at newer trend and technologies.
I hope many immunobio-onclogists's unskewed attention.
An International Symposium Sponsored by the Cancer Research Institute
October 2-4, 2000
Manhattan Conference Center
At the Millennium Broadway, 145 West 44th Street, New York City
The eighth meeting in CRI's Symposia Series will cover a broad range of topics, including:
Tumor antigen identification
Monitoring immune response to tumor antigens
Mechanisms of tumor antigen presentation
Effector cell generation and memory
Tumor escape routes
Vaccine constructs
Cytokine and non-cytokine adjuvants
Current status of clinical trials
A preliminary list of speakers includes:
Lloyd J. Old, M.D., Conference Chairman, Ludwig Institute for Cancer Research, New York, NY
Vincenzo Cerundolo, M.D., Ph.D., John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
Glenn Dranoff, M.D., Dana-Farber Cancer Institute, Boston, MA
Philip D. Greenberg, M.D., University of Washington, Seattle, WA
Alexander Knuth, M.D., Krankenhaus Nordwest, Frankfurt, Germany
Martin C. Mihm, M.D., F.A.C.P., Massachusetts General Hospital, Boston, MA
Haruo Ohtani, M.D., Tohuku University Graduate School of Medical Science, Sendai, Japan
Pedro Romero, Ph.D., Ludwig Institute for Cancer Research, Lausanne, Switzerland
Steven A. Rosenberg, M.D., Ph.D., National Cancer Institute/NIH, Bethesda, MD
Robert D. Schreiber, Ph.D., Washington University School of Medicine, St. Louis, MO
Gerold Schuler, M.D., Dermotologische Universitaet Klinik, Erlanger, Germany
Pramod K. Srivastava, Ph.D., University of Connecticut, Farmington, CT
Tiny comments on CV2000 :
1) This conference is regarded as a best meeting in a field of tumor immunology.
2) The Cancer Research Institute(sponser org.) was founded in 1953 to foster the science of cancer immunology, which is based on the premise that the body's immune system can be mobilized against cancer. This field, which CRI helped pioneer and develop, has been recognized throughout the world as offering great hope for the ultimate prevention and treatment of human cancer.
For nearly five decades, the Institute has been a sustaining force in cancer and immunology research. The Institute has supported nearly 1000 scientists and clinicians at leading universities and research centers worldwide. All such funding decisions are made by its Scientific Advisory Council consisting of 64 of the world's leading immunologists, including five Nobel Prize winners and 18 members of the National Academy of Sciences.
3) I have attended this meeting 2 years(98-99) consecutively.
However, I never seen a Korean immunologist even though this field has been still rapidly progressing.
This year, I am gonna attend and grasp at newer trend and technologies.
I hope many immunobio-onclogists's unskewed attention.